CancerSnoop Research ExplainedAt a glanceFrontline blinatumomab B-ALL: Frontline…

New Oral Drug Rasonque Recommended for Advanced Pancreatic C
CancerSnoop News
Rasonque pancreatic cancer: The European Medicines Agency (EMA) has recommended approving Rasonque, a new pill for adults with metastatic pancreatic cancer who have tried other treatments.
What happened
Rasonque contains daraxonrasib, which works by blocking proteins that help cancer cells grow and survive. This drug targets a common mutation in pancreatic cancer called RAS G12.
In a large study with 500 patients whose cancer worsened after previous treatments, those taking Rasonque lived about 12.4 months on average, nearly double the 6.7 months seen with chemotherapy. Patients also had longer periods without their disease getting worse.
Common side effects included diarrhea, rash, mouth soreness, nausea, and vomiting. This recommendation means Rasonque could soon become available across the European Union, offering new hope for patients with this hard-to-treat cancer.
Who this concerns
This news is important for adults with metastatic pancreatic adenocarcinoma, especially those whose cancer progressed after prior treatment, and their families looking for new options.
What the evidence shows
The EMA's recommendation is based on data from a phase 3 clinical trial of 500 patients showing improved survival and disease control with Rasonque compared to chemotherapy. The drug targets RAS mutations found in most pancreatic cancers.
What remains unclear
While these results are promising, side effects may affect some patients, and individual responses can vary. Final approval depends on the European Commission's decision and further review by each EU country regarding cost and use.
Bottom line
Rasonque represents a potentially better treatment for advanced pancreatic cancer patients who have run out of options, offering longer survival and disease control with manageable side effects.
